In December 2015, Sanofi and MAB Discovery signed a collaboration agreement for the development of antibodies against selected targets.
In May 2014, Synthon and MAB Discovery entered into a multi-target antibody discovery agreement.
In March 2014, MAB Discovery signed a multi-target deal with Genmab A/S for the development of therapeutic antibody products.
In March 2013, MAB Discovery entered into a collaboration with BioNTech of Mainz, Germany to discover monoclonal antibodies to a number of targets.
In July 2012, MAB Discovery entered into an agreement with an undisclosed US biotech company to develop monoclonal antibodies to a number of targets.
In June 2012, MAB Discovery entered into an agreement with Boehringer Ingelheim for the generation of monoclonal antibodies.